利福舒替尼(TNP-2198)这种新型双靶点抗菌药在中国健康受试者和幽门螺杆菌感染患者中的安全性、药代动力学和疗效:四项随机临床试验
四项随机临床试验评估了利福舒替尼在健康受试者和无症状幽门螺杆菌感染患者中的安全性、药代动力学和疗效。利福舒替尼单药或联合治疗总体安全且耐受性良好,400 mg利福舒替尼联合雷贝拉唑和阿莫西林每日两次、疗程14天的三联方案显示出有前景的幽门螺杆菌根除率。
要点
- 利福舒替尼单次50-1000 mg和多次200-600 mg每日两次给药安全性和耐受性良好,多数不良事件为轻度,未报告严重不良事件。
- 利福舒替尼在50-800 mg剂量范围内呈线性药代动力学特征,与联合给药药物之间无明显药代动力学相互作用。
- 试验4中,400 mg利福舒替尼+20 mg雷贝拉唑钠+1 g阿莫西林每日两次、疗程14天的三联方案幽门螺杆菌根除率为95%(95% CI 74-100)。
核心结论
- 利福舒替尼单药和联合治疗在健康受试者和幽门螺杆菌感染患者中总体安全且耐受性良好。
- 400 mg利福舒替尼胶囊、20 mg雷贝拉唑钠肠溶片和1 g阿莫西林胶囊每日两次、疗程14天的三联方案作为幽门螺杆菌感染的新治疗方案显示出有前景的疗效。
研究设计与样本
- 在中国吉林省的一个临床试验中心开展了四项利福舒替尼胶囊临床试验,纳入健康受试者(18-55岁)和无症状幽门螺杆菌感染患者(18-65岁)。
- 试验1为1期双盲、随机、安慰剂对照、单次剂量递增研究,受试者纳入七个剂量组(50 mg、100 mg、200 mg、400 mg、600 mg、800 mg或1000 mg),按4:1比例随机分配至研究药物或安慰剂。
- 试验2为1期双盲、随机、安慰剂对照、多次剂量递增研究,患者纳入三个剂量组(200 mg、400 mg或600 mg),按3:1比例随机分配至研究药物或安慰剂。
- 试验3为2a期开放标签、随机、多次给药、剂量探索研究,患者纳入四个队列之一,按1:1:1:1比例随机分配至利福舒替尼二联或三联方案。
- 试验4为2b期开放标签、随机、多次给药、方案探索研究,患者纳入五个队列之一,按2:2:1:1:2比例随机分配至利福舒替尼二联治疗、三联治疗或对照队列;所有试验均采用区组随机化(区组大小4或8)。
主要发现
- 2019年5月9日至2022年9月14日期间,四项临床试验共纳入78名健康受试者(试验1:每队列10名,按4:1利福舒替尼:安慰剂比例,另加8名用于食物效应队列)和168名无症状幽门螺杆菌感染患者(试验2:每队列16名,按3:1利福舒替尼:安慰剂比例;试验3:每队列10名;试验4:每队列10名或20名)。
- 单次利福舒替尼剂量(50-1000 mg)和多次利福舒替尼剂量(200 mg至600 mg,每日两次),无论单药治疗或与雷贝拉唑和阿莫西林联合给药,均显示出良好的安全性和耐受性特征;大多数不良事件为轻度,未报告严重不良事件。
- 利福舒替尼在50-800 mg剂量范围内呈现线性药代动力学特征,利福舒替尼与联合给药药物之间无明显药代动力学相互作用。
- 进食轻度升高利福舒替尼的血浆浓度-时间曲线下面积(AUC),进食状态下AUC0-t和AUC0-∞的几何均值分别为空腹状态的1.334倍和1.396倍;连续给药后有利福舒替尼轻度蓄积,试验3中二联和三联方案中400 mg利福舒替尼的Rac(AUC)分别为1.37和1.49。
- 试验3中,200 mg、400 mg或600 mg利福舒替尼联合雷贝拉唑每日两次、疗程14天的幽门螺杆菌根除率分别为0%(95% CI 0-31)、30%(7-65)和40%(12-74),确定400 mg利福舒替尼为有效剂量。
关键数值与推荐
- 试验1、2和3的关键主要终点为利福舒替尼的耐受性、安全性和药代动力学。
- 试验4的主要终点为幽门螺杆菌根除率。
- 试验3中,200 mg、400 mg或600 mg利福舒替尼联合雷贝拉唑每日两次、疗程14天的幽门螺杆菌根除率分别为0%(95% CI 0-31)、30%(7-65)和40%(12-74)。
- 试验4中,队列A的三联方案(400 mg利福舒替尼、20 mg雷贝拉唑钠和1 g阿莫西林)每日两次、疗程14天的幽门螺杆菌根除率为95%(95% CI 74-100)。
- 试验4中,三联疗法(600 mg利福舒替尼、20 mg雷贝拉唑钠和1 g阿莫西林)每日三次、疗程7天的幽门螺杆菌根除率为100%(69-100)。
临床怎么用
- 原文未据此给出推荐。
- 作者认为,400 mg利福舒替尼胶囊、20 mg雷贝拉唑钠肠溶片和1 g阿莫西林胶囊每日两次、疗程14天的三联方案作为幽门螺杆菌感染的新治疗方案显示出有前景的疗效。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Due to the rapid development of antimicrobial resistance, the efficacy of most Helicobacter pylori eradication therapies have progressively decreased to an unacceptable level. Rifasutenizol (TNP-2198) is a new molecular entity with a synergistic dual mechanism of action currently under clinical development for the treatment of microaerophilic and anaerobic bacterial infections. We aimed to evaluate the safety, pharmacokinetics, and efficacy of rifasutenizol in healthy Chinese participants and patients with H pylori. METHODS: We conducted four clinical trials of rifasutenizol capsules in healthy participants (aged 18-55 years) and patients with asymptomatic H pylori infection (aged 18-65 years) in a clinical trial centre in Jilin province, China. Trial 1 was a phase 1, double-blind, randomised, placebo-controlled, single ascending dose study, in which participants were enrolled into one of seven rifasutenizol dose groups (50 mg, 100 mg, 200 mg, 400 mg, 600 mg, 800 mg, or 1000 mg) and were randomly assigned in a 4:1 ratio to study drug or placebo. Trial 2 was a phase 1, double-blind, randomised, placebo-controlled, multiple ascending dose study, in which patients were enrolled into one of three rifasutenizol dose groups (200 mg, 400 mg, or 600 mg) and were randomly assigned in a 3:1 ratio to study drug or placebo. Trial 3 was a phase 2a, open-label, randomised, multiple-dose, dose-finding study in which patients enrolled into one of four cohorts were randomly assigned in a 1:1:1:1 ratio to a rifasutenizol dual or triple regimen. Trial 4 was a phase 2b, open-label, randomised, multiple-dose, regimen exploration study, in which patients enrolled into one of five cohorts were randomly assigned in a 2:2:1:1:2 ratio to a rifasutenizol dual therapy, triple therapy, or a control cohort. Block randomisation (block size 4 or 8) was used in all four trials. The key primary endpoints for trials 1, 2, and 3 were the tolerability, safety, and pharmacokinetics of rifasutenizol. For trial 4, the primary endpoint was the eradication rate of H pylori. These four trials were registered at ClinicalTrials.gov (NCT06081699, NCT06081712, NCT06076681, and NCT06076694) and chinadrugtrials.org.cn (CTR20190734, CTR20192553, CTR20212050, and CTR20220625) and are completed. FINDINGS: Between May 9, 2019, and Sept 14, 2022, 78 healthy participants (trial 1: n=10 per cohort in a 4:1 rifasutenizol:placebo ratio; and an additional eight for the food-effect cohort) and 168 patients with asymptomatic H pylori infection (trial 2: n=16 per cohort in a 3:1 rifasutenizol:placebo ratio; trial 3: n=10 per cohort; trial 4: n=10 or n=20 per cohort) were enrolled in the four clinical trials. Single doses of rifasutenizol (50-1000 mg) and multiple doses of rifasutenizol (200 mg to 600 mg, twice a day), either as monotherapy or co-administered with rabeprazole and amoxicillin, showed favourable safety and tolerability profiles. Most adverse events were mild, and no serious adverse events were reported. Rifasutenizol demonstrated a linear pharmacokinetic profile over the dose range of 50-800 mg, and there were no apparent pharmacokinetic interactions between rifasutenizol and the co-administrated drugs. Food intake slightly elevated the area under the plasma concentration-time curve (AUC) of rifasutenizol, and the geometric mean of AUC from time 0 to the last timepoint with a quantifiable concentration (AUC0-t) and AUC from time 0 to infinity (AUC0-∞) in the fed state were 1·334 and 1·396 times of those in the fasted state, respectively. There was mild accumulation after continuous administration of rifasutenizol, and the Rac(AUC) of rifasutenizol 400 mg in the dual and triple regiments in trial 3 were 1·37 and 1·49, respectively. In trial 3, the eradication rates of H pylori with 200 mg, 400 mg, or 600 mg of rifasutenizol in combination with rabeprazole, twice a day for 14 days, were 0% (95% CI 0-31), 30% (7-65), and 40% (12-74), respectively, identifying rifasutenizol 400 mg as the effective dose. In trial 4, H pylori eradication rates with the triple regimen in cohort A (400 mg rifasutenizol, 20 mg rabeprazole sodium, and 1 g amoxicillin) twice a day for 14 days was 95% (95% CI 74-100), and triple therapy (600 mg rifasutenizol, 20 mg rabeprazole sodium, and 1 g amoxicillin) three times a day for 7 days was 100% (69-100). INTERPRETATION: Rifasutenizol monotherapy and combination therapy was generally safe and well tolerated in healthy participants and patients with H pylori infection. A triple regimen of 400 mg rifasutenizol capsules, 20 mg rabeprazole sodium enteric-coated tablets, and 1 g amoxicillin capsules twice a day for 14 days showed promising efficacy as a new treatment regimen for H pylori infection. FUNDING: TenNor Therapeutics and National Natural Science Foundation of China. TRANSLATION: For the Chinese translation of the abstract see Supplementary Materials section.
引用
- Li X, Liu Y, Wang M, et al. Safety, pharmacokinetics, and efficacy of rifasutenizol, a novel dual-targeted antibacterial agent in healthy participants and patients in China with Helicobacter pylori infection: four randomised clinical trials. Lancet Infect Dis. 2024. PMID: 38359854. doi:10.1016/S1473-3099(24)00003-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。